Bio-Rad Laboratories (NYSE:BIO.B) Stock Price Up 3.6% - Time to Buy?

Key Points

• Shares of Bio‑Rad jumped 3.6% to $278.25 on Tuesday, with intraday volume of 152 shares — a 418% increase versus the average session volume of 29 shares.
• The company trades at a relatively low valuation with a market capitalization of $7.51 billion and a P/E of 9.97, while showing low leverage (debt-to-equity 0.16) and strong liquidity (quick ratio 4.19, current ratio 5.62).
• In the most recent quarter Bio‑Rad reported $2.51 EPS on $693.2 million of revenue and delivered a net margin of 29.42%.

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report) shot up 3.6% during trading on Tuesday . The stock traded as high as $278.30 and last traded at $278.25. 152 shares changed hands during mid-day trading, an increase of 418% from the average session volume of 29 shares. The stock had previously closed at $268.55.

Bio-Rad Laboratories Trading Up 3.6%

The firm's fifty day simple moving average is $280.24 and its 200 day simple moving average is $294.64. The stock has a market capitalization of $7.51 billion, a P/E ratio of 9.97 and a beta of 1.02. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.19 and a current ratio of 5.62.

Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The company reported $2.51 EPS for the quarter. Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.The company had revenue of $693.20 million during the quarter.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad's product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.